Incidence of severe urinary tract infections not increased by initiating sodium–glucose cotransporter 2 inhibitors-Reference-Cited by-同舟云学术

Incidence of severe urinary tract infections not increased by initiating sodium–glucose cotransporter 2 inhibitors

Published:2020-01-07 Issue:3 Volume:11 Page:530-531
ISSN:2040-1116
Container-title:Journal of Diabetes Investigation
language:en
Short-container-title:J Diabetes Investig

Author:

Yokoyama Hiroki¹^ORCID

Affiliation:

1. Jiyugaoka Medical Clinic Internal Medicine Obihiro Japan

Publisher

Wiley

Subject

General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdi.13189

Reference5 articles.

1. U.S. Food and Drug Administration. FDA drug safety communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tractinfections. Updated 19 January 2018. Available from: www.fda.gov/drugs/drug‐safety‐and‐availability/fda‐drug‐safety‐communication‐fda‐revises‐labels‐sglt2‐inhibitors‐diabetes‐include‐warnings‐abouton Accessed June 15 2019.

2. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis

3. Sodium–Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections

4. Incidence and risk of vaginal candidiasis associated with sodium-glucose cotransporter 2 inhibitors in real-world practice for women with type 2 diabetes

5. Prevalence of Asymptomatic Bacteriuria and Associated Host Factors in Women with Diabetes Mellitus

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emphysematous Cystitis and Urinary Retention in a Male Patient With Diabetes Mellitus Type 2 Treated With Empagliflozin;AACE Clinical Case Reports;2022-07

2. Heart Failure in Diabetes Mellitus: An Updated Review;Current Pharmaceutical Design;2020-12-30